Sensorimotor- and whole-body vibration training have the potential to reduce motor- and sensory symptoms of Chemotherapy-induced peripheral neuropathy – a randomized controlled trial

Sensorimotor- and whole-body vibration training have the potential to reduce motor- and sensory symptoms of Chemotherapy-induced peripheral neuropathy – a randomized controlled trial - VICE

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00013027

Enrollment

Registered

2017-11-06

Start date

2013-07-22

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chemotherapy-induced peripheral neuropathy (CIPN)

Interventions

Group 1: Sensorimotor training: 10 patients with Chemotherapy-induced peripheral neuropathy receive supervised sensorimotor training twice a week for six weeks. Group 2: whole body vibration training

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: = 18 years old, oncological disease, Chemotherapy-induced peripheral neuropathy = grade 1, healthy controls have to have the same age (+/- 1 year) and gender

Exclusion criteria

Exclusion criteria: - neuropathy of other derivation (Diabetes, HIV etc) - All Illnesses that prevent physical activity - Contraindications for whole body vibration (Osteosynthesis, instable osteolysis, acute thrombosis, acute prolaps, implants in lower body, pregnancy, acute wounds, fracture of lower extremity in past 2 years etc - planed operation - no signed consent or willingness to allow anonymous data collection - language restrictions or psychological impairments that prevent the understanding of the written consent and/or instructions given - uncontrolled cerebral fits - CNS metastatsis

Design outcomes

Primary

Measure	Time frame
All assessments were performed by a blinded examiner at baseline (T0) and after 6 weeks (T1). Primary endpoint is a short clinical test battery: (Achilles- and Patella tendon reflexes (assessed with a reflex hammer), peripheral deep sensitivity (tuning fork), proprioception, sense of position and lower leg strength)	—

Secondary

Measure	Time frame
Secondary endpoints are also assessed prior to the intervention (baseline T0) and after the intervention (six weeks later T1): Nerve conduction velocity and amplitude of the N. tibialis and N. suralis, balance control (cumulative sway path in cm, assessed on force plate), neuropathic pain (PAIN Detect questionnaire), subjective report of CIPN related symptoms (FACT-gog-ntx questionnaire), Quality of life (EORTC-QLQ-C-30 questionnaire), level of physical activity (FFKA questionnaire)	—

Measure

Time frame

Secondary endpoints are also assessed prior to the intervention (baseline T0) and after the intervention (six weeks later T1): Nerve conduction velocity and amplitude of the N. tibialis and N. suralis, balance control (cumulative sway path in cm, assessed on force plate), neuropathic pain (PAIN Detect questionnaire), subjective report of CIPN related symptoms (FACT-gog-ntx questionnaire), Quality of life (EORTC-QLQ-C-30 questionnaire), level of physical activity (FFKA questionnaire)

—

Countries

Germany

Contacts

Public ContactFiona Streckmann

Deutsche Sporthochschule Köln, Universität Basel

f.streckmann@dshs-koeln.de022149825450

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Mar 5, 2026